HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD. Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Share Price
Equities
300255
CNE1000016C2
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.97 CNY | +1.70% |
|
+23.53% | -7.99% |
| Sales 2022 | 2.34B 323M 25.77B | Sales 2023 | 1.41B 195M 15.56B | Capitalization | 11.96B 1.65B 132B |
|---|---|---|---|---|---|
| Net income 2022 | 17M 2.35M 188M | Net income 2023 | -1.24B -171M -13.68B | EV / Sales 2022 | 2.88 x |
| Net Debt 2022 | 1.69B 234M 18.67B | Net Debt 2023 | 2.1B 289M 23.12B | EV / Sales 2023 | 9.96 x |
| P/E ratio 2022 |
274
x | P/E ratio 2023 |
-9.64
x | Employees | 1,424 |
| Yield 2022 |
0.09% | Yield 2023 |
-
| Free-Float | 41% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.70% | ||
| 1 week | +23.53% | ||
| Current month | +4.63% | ||
| 1 month | +2.92% | ||
| 3 months | +16.44% | ||
| 6 months | -8.28% | ||
| Current year | -7.99% |
1 week
9.54
13.00
1 month
9.1813.00
Current year
7.5614.34
1 year
4.3017.98
3 years
4.3017.98
5 years
4.3017.98
10 years
3.8819.28
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Wang
DFI | Director of Finance/CFO | 47 | 31/08/09 |
Zheng Gang Qie
BRD | Director/Board Member | 53 | 23/06/20 |
Yun Xia Sun
BRD | Director/Board Member | 43 | 19/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiang Jun Wang
BRD | Director/Board Member | 60 | 29/12/21 |
Yan Bin Liu
BRD | Director/Board Member | 62 | 30/04/09 |
De Ying Cao
BRD | Director/Board Member | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 11.97 | +1.70% | 106,347,200 |
| 25/04/24 | 11.77 | +19.98% | 45,217,960 |
| 24/04/24 | 9.81 | +1.13% | 23,111,060 |
| 23/04/24 | 9.7 | -2.32% | 23,250,110 |
| 22/04/24 | 9.93 | +2.48% | 30,532,020 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Hebei Changshan Biochemical Pharmaceutical Co., Ltd is principally engaged in the research, development, manufacture and distribution of bio-pharmaceutical products. The Company primarily provides heparin product series. The Company provides sodium heparin active pharmaceutical ingredients (APIs) and hydro-acupuncture preparations. The Company's products are applied primarily in the prevention and treatment of cerebral vascular diseases, hardened arteries, myocardial infarction and phlebitis, among others. It distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
28/04/2024
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.99% | 1.52B | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| +56.46% | 25.23B | |
| -15.26% | 15.36B | |
| -9.14% | 11.95B | |
| -16.72% | 11.6B | |
| -43.00% | 11.51B | |
| +6.37% | 8.71B | |
| -7.02% | 8.12B |
- Stock Market
- Equities
- 300255 Stock
